Voloridge Investment Management LLC Has $7.09 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Voloridge Investment Management LLC trimmed its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 33.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 171,537 shares of the company's stock after selling 85,242 shares during the period. Voloridge Investment Management LLC owned 0.36% of Mirum Pharmaceuticals worth $7,093,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Woodline Partners LP lifted its stake in shares of Mirum Pharmaceuticals by 22.2% during the fourth quarter. Woodline Partners LP now owns 404,404 shares of the company's stock worth $16,722,000 after purchasing an additional 73,399 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Mirum Pharmaceuticals during the 4th quarter worth approximately $897,000. Tema Etfs LLC purchased a new position in Mirum Pharmaceuticals in the 4th quarter worth approximately $1,735,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Mirum Pharmaceuticals in the fourth quarter valued at approximately $35,000. Finally, ProShare Advisors LLC raised its stake in shares of Mirum Pharmaceuticals by 31.5% during the fourth quarter. ProShare Advisors LLC now owns 13,457 shares of the company's stock valued at $556,000 after purchasing an additional 3,227 shares during the period.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, Director Patrick J. Heron bought 1,335 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average cost of $45.57 per share, for a total transaction of $60,835.95. Following the transaction, the director now directly owns 163,643 shares in the company, valued at $7,457,211.51. The trade was a 0.82% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Peter Radovich sold 7,879 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $348,330.59. Following the transaction, the chief operating officer now owns 18,672 shares of the company's stock, valued at $825,489.12. This trade represents a 29.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 92,764 shares of company stock worth $4,109,161. Insiders own 14.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on MIRM shares. HC Wainwright reaffirmed a "buy" rating and set a $73.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, May 19th. JMP Securities lifted their target price on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research report on Friday, May 9th. Robert W. Baird increased their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. Finally, Raymond James restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. Ten analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Mirum Pharmaceuticals has a consensus rating of "Buy" and an average target price of $60.73.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM traded up $0.26 during mid-day trading on Thursday, hitting $43.99. The company had a trading volume of 345,703 shares, compared to its average volume of 519,888. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.83 and a 12 month high of $54.23. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -21.77 and a beta of 0.95. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The firm's 50 day simple moving average is $42.74 and its two-hundred day simple moving average is $44.64.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. The company had revenue of $111.59 million for the quarter, compared to analysts' expectations of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm's quarterly revenue was up 61.2% compared to the same quarter last year. During the same period last year, the business posted ($0.54) earnings per share. As a group, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.